Up to 70% of pregnant women with hereditary AT deficiency may experience thromboembolic complications1,2


PREGNANCY CASE STUDY: STEPHANIE

Age:28 years

Height5'4"

Weight154 lb (70 kg)



 

Family History: Peripheral artery disease, fatal massive pulmonary embolism, deep vein thrombosis, miscarriage

Chief Complaint: 39 weeks pregnant with AT deficiency and presents at hospital for induction of labor

Complication: Hereditary AT deficiency (AT activity 57% of normal)

Treatment Goals and Plan: To deliver a full-term infant, while preventing pregnancy-related venous thromboembolism (VTE) due to hereditary AT deficiency. AT activity will be increased to between 80% and 120% during the delivery. She will be administered Thrombate IIIᆴ (antithrombin III [human]) before administering regional anesthesia for pain relief. She will continue to receive Thrombate III for 1 week postpartum to decrease the risk of VTE

 

For reimbursement questions,
call the Reimbursement Helpline
at 1-877-827-3462


 


Thrombate III® (antithrombin III [human]) is indicated for the treatment of patients with hereditary antithrombin deficiency in connection with surgical or obstetrical procedures or when they suffer from thromboembolism.

In clinical studies, the most common adverse events were dizziness, chest discomfort, nausea, and dysgeusia.

The anticoagulant effect of heparin is enhanced by concurrent treatment with Thrombate III in patients with hereditary AT-III deficiency. Thus, in order to avoid bleeding, reduced dosage of heparin is recommended during treatment with Thrombate III.

Thrombate III is made from human plasma. Plasma products carry a risk of transmitting infectious agents, such as viruses, and theoretically, the Creutzfeldt-Jakob disease (CJD) agent, despite steps designed to reduce this risk. No cases of transmission of viral disease or CJD have ever been identified for Thrombate III.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.


References

  1. Thrombate III® (antithrombin III [human]) Prescribing Information. Grifols.
  2. Hellgren M, Tengborn L, Abildgaard U. Pregnancy in women with congenital antithrombin III deficiency: experience of treatment with heparin and antithrombin. Gynecol Obstet Invest . 1982;14(2):127-141.